Trial · NCT00086996

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

NCT00086996, Phase 2, Completed, SWOG Cancer Research Network; results first posted 2012-04-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction. Trials, record NCT00086996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00086996

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
NCT number: NCT00086996
Status: Completed
Phases: Phase 2
Enrollment: 98 participants, actual
Lead sponsor: SWOG Cancer Research Network
Conditions: Esophageal Cancer
Interventions: fluorouracil, oxaliplatin, conventional surgery, radiation therapy
First posted: 2004-07-12
Last updated: 2013-10-11
Results first posted: 2012-04-03

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Pathological Complete Response	10-16 weeks after beginning study treatment	Complete pathologic response assessed after chemoradiotherapy and surgery, defined as no evidence of residual disease on path review. Patients who did not receive surgery are assumed to have not responded.
Secondary	Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Up to 3 years	Only adverse events that are possibly, probably or definitely related to study drug are reported.
Secondary	Overall Survival	0-5 years	Measured from time of registration to death, or last contact date
Secondary	Progression-free Survival	0-3 years	measured from date of registration to time of first documentation of progression by Response Evaluation Criteria in Solid Tumors (RECIST), death, or last contact date.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Pathological Complete Response	10-16 weeks after beginning study treatment	Eligible patients	participants	NUMBER
SECONDARY	Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Up to 3 years	Eligible patients who received any treatment and were assessed for toxicity were included in the adverse event summaries. Any Common Terminology Criteria for Adverse Events (CTCAE) v3.0 event of Grade 3 (severe), Grade 4 (life threatening), or Grade 5 (fatal) which were deemed to be related to protocol treatment are included.	Participants	NUMBER
SECONDARY	Overall Survival	0-5 years	eligible patients	months	MEDIAN
SECONDARY	Progression-free Survival	0-3 years	eligible patients	months	MEDIAN

Source ClinicalTrials.gov

Results by group70

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Pathological Complete Response	Chemo Plus RT, Surgery, Chemo		26	participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Adult respiratory distress syndrome (ARDS)	4	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Anorexia	15	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	CNS cerebrovascular ischemia	1	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Calcium, serum-low (hypocalcemia)	2	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Cardiac troponin T (cTnT)	1	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Cardiac-ischemia/infarction	1	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Chyle or lymph leakage	1	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Confusion	1	Participants
Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug	Chemo Plus RT, Surgery, Chemo	Cough	1	Participants

1 to 10 of 70Source ClinicalTrials.gov

See all 70 results by group

Participant flow5

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Chemo Plus RT, Surgery, Chemo	98
Overall Study	Eligible	Chemo Plus RT, Surgery, Chemo	93
Overall Study	Eligible and Began Protocol Therapy	Chemo Plus RT, Surgery, Chemo	93
Overall Study	COMPLETED	Chemo Plus RT, Surgery, Chemo	34
Overall Study	NOT COMPLETED	Chemo Plus RT, Surgery, Chemo	64

Source ClinicalTrials.gov

Adverse events78

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Hemoglobin	Blood and lymphatic system disorders	Chemo Plus RT, Surgery, Chemo	67	93
other	SVT and nodal arrhythmia - Atrial fibrillation	Cardiac disorders	Chemo Plus RT, Surgery, Chemo	16	93
other	SVT and nodal arrhythmia - Sinus tachycardia	Cardiac disorders	Chemo Plus RT, Surgery, Chemo	8	93
other	Constipation	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	28	93
other	Diarrhea	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	59	93
other	Distention/bloating, abdominal	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	5	93
other	Dysphagia (difficulty swallowing)	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	40	93
other	Esophagitis	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	10	93
other	Gastritis (including bile reflux gastritis)	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	5	93
other	Gastrointestinal-Other (Specify)	Gastrointestinal disorders	Chemo Plus RT, Surgery, Chemo	8	93

1 to 10 of 78Source ClinicalTrials.gov

See all 78 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Chemo Plus RT, Surgery, Chemo
Total, other adverse events	Chemo Plus RT, Surgery, Chemo	93	93
Total, serious adverse events	Chemo Plus RT, Surgery, Chemo	7	93

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22025151	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA032102	Southwest Oncology Group Treatment Grant	BLANKE, CHARLES D.	OREGON HEALTH & SCIENCE UNIVERSITY	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00086996

GET https://conductscience.org/api/trials/v1/NCT00086996/results?page=2

API reference For AI assistants